News: ARX Aroa Biosurgery Says FY24 Product Revenue Guidance Maintained At NZ$72-75 Mln, page-2

Terrific company, great products. Consistent results. Baffling share price (but with low volumes)

Staff costs are too high but presumably a large part is the sales force to drive further growth. It appears that there are up to 150 sales reps who probably cost $20M (NZD) . Hopefully this investment delivers top line growth, else perhaps better to trim the sales team and other staff and improve profitability and start getting measured in Growth, P/E and Cash terms which probably will uplift share price in this environment.